Less than a week after a federal appeals court heard arguments in New York state’s challenge of an Actavis plc plan to switch Alzheimer’s patients to a new version of the drug Namenda, a Philadelphia district judge on Thursday rejected similar “product-hopping” allegations, clearing Warner Chilcott plc of antitrust liability in a separate case.
The same day, Actavis’ lawyers at Arnold & Porter pounced on the Philadelphia decision, suggesting that it supports their defense.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
